Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Clinical trial NCT06109779 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06109779
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-04
- Primary completion
- 2029-01-02
- Enrollment
- 760
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.